cosibelimab   Click here for help

GtoPdb Ligand ID: 13676

Synonyms: CK-301 | CK301 | cosibelimab-ipdl | Unloxcyt®
Approved drug
cosibelimab is an approved drug (FDA (2024))
Compound class: Antibody
Comment: Cosibelimab (CK-301) is a human anti-programmed cell death 1 ligand 1 (PD-L1) monoclonal antibody. It belongs to the immune checkpoint inhibitor class of anti-tumour drugs. Cosibelimab blocks inhibitory PD-L1 regulation of the anti-tumour immune response and induces antibody-dependent cell-mediated cytotoxicity (ADCC).
Peptide sequence alignments indicate identity between peptide sequences for the INN cosibelimab and those for antibody CTI-48 as claimed in patent US10590199B2 [1].
Classification Click here for help
Compound class Antibody
Approved drug? Yes. FDA (2024)
International Nonproprietary Names Click here for help
INN number INN
11107 cosibelimab
Synonyms Click here for help
CK-301 | CK301 | cosibelimab-ipdl | Unloxcyt®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 946
Other databases
GtoPdb PubChem SID 507750310
Search PubMed clinical trials cosibelimab
Search PubMed titles cosibelimab
Search PubMed titles/abstracts cosibelimab